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Vaccine vectorWe have analyzed the potential of virus-like particles (VLPs) from rabbit hemorrhagic disease virus (RHDV)
as a delivery system for foreign T cell epitopes. To accomplish this goal, we generated chimeric RHDV-VLPs
incorporating a CD8+ T cell epitope (SIINFEKL) derived from chicken ovalbumin (OVA). The OVA epitope was
inserted in the capsid protein (VP60) of RHDV at two different locations: 1) the N-terminus, predicted to be
facing to the inner core of the VLPs, and 2) a novel insertion site predicted to be located within an exposed
loop. Both constructions correctly assembled into VLPs. In vitro, the chimeric VLPs activated dendritic cells for
TNF-α secretion and they were processed and presented to speciﬁc T cells. In vivo, mice immunized with the
chimeric VLPs without adjuvant were able to induce speciﬁc cellular responses mediated by cytotoxic and
memory T cells. More importantly, immunization with chimeric VLPs was able to resolve an infection by a
recombinant vaccinia virus expressing OVA protein.© 2009 Elsevier Inc. All rights reserved.Introduction
Caliciviruses cause a variety of diseases in humans and animals
(Green, 2006). The family Caliciviridae has been divided into four
genera:Norovirus, Sapovirus,Vesivirus andLagovirus. Rabbit hemorrhagic
disease virus (RHDV), the prototype strain of the genus Lagovirus, is the
causative agent of a highly infectious disease of rabbits (Angulo and
Barcena, 2007; Cooke, 2002; Fenner and Fantini, 1999). Infected rabbits
usually die within 48 to 72 h of necrotizing hepatitis. The virions
(∼40 nm in diameter) are non-enveloped and icosahedral and have a
7.4-kb single-stranded positive-sense RNA genome. The genomic RNA is
organized into two open reading frames (ORFs). The ﬁrst ORF encodes a
polyprotein that is processed giving rise to severalmature nonstructural
proteins and the capsid protein subunit of 60 kDa (VP60) (Meyers et al.,
2000; Thumfart and Meyers, 2002). The second ORF encodes a small
minor structural protein, VP2. The RHDV-VP60 protein, expressed in
several heterologous systems, has been shown to induce full protection
of rabbits against a lethal challenge with RHDV (Barcena et al., 2000;
Boga et al., 1994; Boga et al., 1997; Castanon et al., 1999; Fernandez-
Fernandez et al., 2001; Laurent et al., 1994; Perez-Filgueira et al., 2007).ntoya).
ll rights reserved.A major breakthrough in calicivirus research was the ﬁnding that
the capsid protein of Norwalk virus (NV, the prototypic strain of the
genus Norovirus), expressed in insect cells self-assembled into virus-
like particles (VLPs) that are morphologically and antigenically
identical to the infectious particles (Green et al., 1993; Jiang et al.,
1992). Subsequently, recombinant calicivirus VLPs from the four
genera have been reported (Chen et al., 2004; DiMartino,Marsilio, and
Roy, 2007; Jiang et al., 1999; Laurent et al., 1994). The three-
dimensional structure of several calicivirus recombinant VLPs as well
as authentic virions has been determined to low resolution by cryo-
electronmicroscopyand three-dimensional reconstruction techniques
(Barcena et al., 2004; Chen et al., 2004; Prasad et al., 1994a, 1994b).
These studies showed that caliciviruses are 35–40 nm in diameterwith
a T=3 icosahedral capsid formed by 90 dimers of the capsid protein,
which surround 32 large hollows or cup-shaped depressions. X-ray
crystallographic structures are available for NV VLPs and San Miguel
sea lion virus (SMSV, the prototypic strain of the genus Vesivirus)
(Chen et al., 2006; Prasad et al., 1999). Each capsid monomer has two
major domains, the S (shell) and P (protruding) domains, linked by a
hinge region. TheN-terminal S domain is responsible for the formation
of the continuous shell of the capsid, while the C-terminal P domain
forms the arch-like structures extending from the shell. The P domain
can be further divided into P1 and P2 subdomains, with P2 subdomain
located on the surface of the capsid.
Generally speaking, VLPs are appealing as vaccine candidates
because their inherent properties (ie, multimeric antigens and
304 E. Crisci et al. / Virology 387 (2009) 303–312particulate structure) are optimal for the induction of an efﬁcient
immune response. The most important advantages of VLP-based
vaccines as a speciﬁc type of subunit vaccines are: 1) the absence of
infectivity/reversion to virulent phenotype since they contain no
genetic material, 2) the robust immunogenicity, due to their
repetitive, high density display of epitopes, and 3) their ability to
elicit both protective neutralizing antibodies and cellular-mediated
immunity. Some examples of VLPs that have been successfully used
for vaccine development and have been licensed commercially
include VLPs derived from hepatitis B virus (HBV) and human
papilloma virus (HPV) (recently reviewed in Chackerian, 2007;
Jennings and Bachmann, 2007; Ramqvist, Andreasson, and Dalianis,
2007; Spohn and Bachmann, 2008). In addition to being used to
induce immune responses against the particle itself, VLPs have been
successfully used as platforms for inducing immune responses against
inserted foreign immunogenic epitopes (chimeric VLPs) (Dalsgaard et
al., 1997; Langeveld et al., 2001; Neirynck et al., 1999; Netter et al.,
2001; Sedlik et al., 1997; Varsani et al., 2003; Woo et al., 2006).
We have previously performed an exhaustive structural analysis of
the RHDV capsid protein and obtained a pseudo-atomicmodel of VP60
protein (Barcena et al., 2004). Our group and others have shown that
VP60 protein can accommodate insertions of foreign amino acid
sequences at both, the N- and C-terminal regions, without disrupting
VLP formation (Barcena et al., 2004; El Mehdaoui et al., 2000;
Nagesha, Wang, and Hyatt, 1999), raising the possibility of using
RHDV-VLPs as foreign epitope carriers for vaccine development. In
addition, this structural focus allowed us to infer speciﬁc sites at the
outermost region of VP60 as potential insertion sites for foreign
epitopes.
Here we report the generation of recombinant chimeric RHDV-
VLPs incorporating a well deﬁned CD8+ T cell epitope correspond-
ing to aa 257–264 (SIINFEKL) from chicken ovalbumin (OVA). This
epitope is restricted for MHC class I H-2Kb presentation (Rotzschke
et al., 1991). The foreign epitope was inserted at two different
locations: 1) at the N-terminus of VP60 protein, which is predicted
to be buried in the internal face of the VLPs, and 2) at a novelFig. 1. Schematic representation and expression of the recombinant VP60 constructs used i
residues. The chimeric proteins VP60-2OVA and VP60-306OVA harbour the depicted foreign
(B) H5 cells were infected by wild-type baculovirus (WT) or the indicated recombinant ba
brilliant blue staining. Molecular weight markers (MW; ×103 Da) are given on the left.insertion site between amino acid positions 306 and 307 of VP60
protein, which is predicted to be located within an exposed loop at
the P2 subdomain of VP60 protein. We analyzed the immunogenic
potential of both chimeric VLPs (RHDV-VLPs-OVA) in vitro and in
vivo. Results of in vitro assays showed that RHDV-VLPs activated
dendritic cells (DCs), as determined by analysis of TNF-α secretion.
Furthermore, DCs were able to process and present SIINFEKL
peptide from RHDV-VLPs-OVA for CD8+ speciﬁc recognition. Both
chimeric RHDV-VLPs were also analyzed in vivo as vaccine vectors
in the total absence of adjuvant. Interestingly, RHDV-VLPs-OVA
were able to stimulate speciﬁc IFNγ-producing cell priming and to
generate a powerful and speciﬁc cytotoxic response in vivo.
Moreover, mice inoculated with RHDV-VLPs-OVA were able to
control an infection by a recombinant vaccinia virus expressing
OVA (VV-OVA) in target organs.
Results
Generation of RHDV recombinant particles
In order to analyze the potential of RHDV-VLPs as a delivery system
for foreign T cell epitopes we produced recombinant baculoviruses
expressing different VP60 constructs (Fig. 1). The foreign amino acid
sequence inserted: GSQLESIINFEKLTEGS (17 aa) contained the T cell
epitope SIINFEKL, ﬂanked by its natural sequences in the OVA protein
(three and two amino acids ﬂanking the N and C terminus of the OVAT
cell epitope, respectively), to promote the correct processing of the
immunogenic epitope by antigen-presenting cells (Rueda et al., 2004).
In addition, the OVA derived sequence was ﬂanked by amino acids
glycine and serine (GS). This two-residue sequence, encoded by the
DNA sequence of BamHI restriction site, might constitute a ﬂexible
linker that facilitates capsid assembly. The foreign sequence was
generated by annealing two complementary oligonucleotides, which
were inserted at unique BamHI restriction sites engineered by site-
directed mutagenesis at deﬁned locations in VP60 gene, as described
in Materials and methods.n this study. (A) Scheme of each construct showing names and numbers of amino acid
peptide sequence containing de OVA derived T cell epitope at the indicated positions.
culoviruses. The infected-cell lysates were analyzed by SDS-10% PAGE and Coomassie
Fig. 2. Analysis of chimeric VP60 particles by negative staining and SDS-PAGE. Electron
microscopy of negatively stained puriﬁed chimeric VP60 particles (A) VP60-2OVA and
(B) VP60-306OVA. Puriﬁed particles were analyzed for protein content by SDS-10%
PAGE and stained with Coomassie brilliant blue (insets). Scale bar, 100 nm.
Fig. 3. Bone marrow derived DCs secreted TNF-α after incubation with control and
chimeric RHDV-VLPs at different concentrations. The column colours indicate the
different RHDV-VLPs: RHDV-VLP (white), RHDV-VLP-2 (grey) and RHDV-VLP-306
(black). Dotted line indicates background level of TNF-α secretion by untreated cells
and error bars representing one standard deviation (SD) above the mean. Data are
representative of two independent experiments.
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locations within the VP60 protein (Fig. 1A) on the basis of structural
considerations. A chimeric mutant was generated by inserting the
foreign sequence between amino acid positions 2 and 3 of VP60
protein sequence (VP60-2OVA). According to the structural model of
RHDV capsid (Barcena et al., 2004), the N-terminus of VP60 protein
is facing to the inner core of the viral capsid. Another chimeric
mutant was produced by inserting the foreign peptide sequence
between amino acid positions 306 and 307 of VP60 protein (VP60-
306OVA). This novel insertion site was predicted based on the
structural model of VP60 protein (Barcena et al., 2004), where this
site would be part of an exposed loop at the P2 subdomain of VP60
protein, and thus might be a suitable location for inserting
heterologous amino acid sequences without altering the ability of
the protein to form VLPs.
Expression of the VP60 constructs in H5 insect cell cultures
infected with the corresponding recombinant baculoviruses was
veriﬁed by SDS-10% PAGE. As shown in Fig. 1B, extracts from insect
cells infected with recombinant baculoviruses harbouring VP60
constructs exhibited a major protein band with the expected size of
∼60 kDa, which was not present in wild-type baculovirus-infected
cells. As expected, the chimeric VP60 constructs containing the OVA
derived epitope displayed a slightly slower electrophoretic mobility
than the VP60 protein, reﬂecting the presence of the inserted
heterologous peptide sequence. Monoclonal antibodies directed
against RHDV-VP60 protein speciﬁcally detected baculovirus-
expressed VP60 protein as well as the chimeric mutants by ELISA
and Western blotting (data not shown).
To determine whether the chimeric VP60 constructs self-
assembled into VLPs, supernatants from infected H5 cell cultures
were subjected to CsCl-gradient centrifugation and characterized by
electron microscopy (Fig. 2). Negatively stained fractions enriched in
the recombinant VP60 constructs (Fig. 2, insets), revealed VLPs of
approximately 40 nm in diameter, which were morphologically
identical to the VLPs formed by the native VP60 protein (data not
shown). Thus, three different RHDV-derived VLPs were generated for
our analysis: the native VLPs (RHDV-VLP), the chimeric VLPs
harbouring the immunogenic epitope at the N-terminus of VP60
protein (RHDV-VLP-2) and the chimeric VLPs with the immunogenic
epitope inserted between residues 306 and 307 of the capsid protein
(RHDV-VLP-306). The yield of the puriﬁed chimeric VLPs was
estimated to be around 5 mg/109 cells, which is within the range of
that previously reported for other calicivirus VLPs (Ball et al., 1998;
Guo et al., 2001; Jiang et al., 1995; Laurent et al., 1994).Antigen presentation of VLP exogenous antigenic peptides by dendritic
cells in vitro
Once both chimeric and control RHDV-VLPs were generated, we
ﬁrstly investigated whether they were able to activate murine bone
marrow derived dendritic cells (BM-DCs) in vitro. When DCs
internalize proteins to stimulate T cell responses, the DCs must
undergo maturation and migrate from the periphery to regional
lymph nodes. It is also well established that DCs are a signiﬁcant
source of a wide range of cytokines that are secreted in response to
various stimuli, e.g., viruses or bacteria and their products. To
investigate whether RHDV-VLPs were capable of activating DCs and
therefore to induce pro-inﬂammatory cytokine production, TNF-α
levels were determined in supernatants of BM-DCs cultured either for
6 h (data not shown) or overnight in the presence or absence of
different concentrations of RHDV-VLPs. In fact, all RHDV-VLPs induced
TNF-α secretion in a dose dependent manner (Fig. 3), indicating a
certain degree of BM-DCs activation after incubation with the VLPs.
Since it has been demonstrated that the presence of contaminating
baculovirus in VLP preparations may induce potent immune
responses that could be erroneously attributed to the VLPs (Hervas-
Stubbs et al., 2007), we also analyzed as a control, material prepared
from insect cells infected with wild-type baculovirus subjected to
the same puriﬁcation procedure as the VLPs (mock VLPs). The average
of TNF-α production induced by mock VLPs was 116.6 pg/ml±12
(mean±SD), which was close to background levels (untreated DCs
44.29 pg/ml±10).
DCs have been recognized as being the most potent antigen-
presenting cells (APCs) capable of stimulating naïve T cells. Therefore,
we analyzed whether DCs could process RHDV-VLPs-OVA and present
the OVA257-264-H2-Kb MHC-I complex to a speciﬁc CD8+ T cell (B3Z)
hybridoma, as the ﬁrst step of cytotoxic T cells (CTL) induction, using
an antigen presentation assay. B3Z hybridoma speciﬁcally recognizes
SIINFEKL peptide presented in combination with H2-Kb MHC-I
(Karttunen, Sanderson, and Shastri, 1992) thereby releasing IL-2 in
the culture supernatants. Serial dilutions of SIINFEKL peptide were
added to BM-DCs and IL-2 levels in the supernatants were recorded as
a measure of antigen presentation in the assay. As shown in Fig. 4A,
SIINFEKL peptide was speciﬁcally recognized when exogenously
added to BM-DCs for antigenic presentation to B3Z hybridome, in a
dose dependent manner. Under our experimental conditions,
Fig. 5. Frequency of SIINFEKL-speciﬁc IFN-γ-producing cells in the spleen of treated
mice. Groups of three mice were twice inoculated with 8 or 40 μg of the RHDV-VLPs and
speciﬁc IFN-γ-producing cells were measured by ELISPOT assay. The column colours
indicate the different RHDV-VLPs: RHDV-VLP (white), RHDV-VLP-2 (grey) and RHDV-
VLP-306 (black). The data shown are the means of results obtained in groups of three
mice, with the error bars representing one standard deviation above the mean. Data are
representative of two independent experiments.
Fig. 4. Mouse DCs are able to process and present SIINFEKL peptide for CD8+ speciﬁc
recognition in vitro in a dose dependent manner. (A) C57Bl/6 BM-DCs were incubated
for 6–7 h in the presence of the indicated concentration of synthetic SIINFEKL peptide,
and IL-2 released was measured by ELISA. (B) IL-2 released after VLP incubation with
C57Bl/6 BM-DCs at different concentrations. The colours indicate the different VLPs:
RHDV-VLP (white), RHDV-VLP-2 (grey) and RHDV-VLP-306 (black). The data shown are
the means of results obtained in triplicate wells and error bars representing one
standard deviation (SD) above the mean. Data are representative of three independent
experiments.
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(Fig. 4A).
When BM-DCs were incubated with chimeric VLPs containing the
SIINFEKL antigenic peptide (RHDV-VLP-2 and RHDV-VLP-306), IL-2
productionwas detected, reﬂecting speciﬁc antigen presentation from
both chimeric RHDV-VLPs. No speciﬁc recognition was detected from
BM-DCs incubated with the native control VLPs (RHDV-VLP) (Fig. 4B).
Antigen presentation showed a dose dependent pattern. Whereas
antigenic peptide presentation was detected when BM-DCs were
incubated with RHDV-VLP-2 at the two highest concentrations used
(10 and 2 μg/ml), presentation of SIINFEKL peptide from RHDV-VLP-
306 was only detected at 10 μg/ml (Fig. 4B). Thus, insertion of the
SIINFEKL peptide in the amino terminal position (RHDV-VLP-2) seems
to favour processing and presentation by DCs in comparison with
SIINFEKL insertion at the exposed loop (RHDV-VLP-306).
All in all, our data indicate that BM-DCs were able to efﬁciently
process and present SIINFEKL peptide from recombinant RHDV-VLPs-
OVA for CD8+ speciﬁc recognition in a dose- and insert position-
dependent manner.
Induction of cellular responses by recombinant VLPs in mice
The results of SIINFEKL presentation by BM-DCs in vitro led us to
investigate whether the chimeric RHDV-VLPs expressing SIINFEKL
peptide in two different positions induced any speciﬁc immunity inmice. Groups of three C57BL/6 mice were immunized twice by
intraperitoneal injections of either 8 or 40 μg of each chimeric RHDV-
VLPs-OVA or control RHDV-VLPs in PBS without adjuvant. A group of
mice infected with VV-OVA was used as a positive control. Taking
into account that SIINFEKL sequence is an immunodominant T cell
epitope in C57Bl/6 mice (possessing H2-Kb MHC-I), it was
conceivable to assume that a good vaccine vector carrying such
epitope would induce speciﬁc IFN-γ-secreting cells and/or cytotoxic
T cells (CTLs). Indeed, two weeks after the last inoculation of mice
with RHDV-VLPs-OVA, speciﬁc IFN-γ-secreting cells were detected in
spleens of mice by ELISPOT (Fig. 5). They exhibited a dose dependent
pattern. At the highest dose of RHDV-VLPs-OVA used, both chimeric
constructs induced similar numbers of IFN-γ-secreting cells. Notice-
ably, signiﬁcant numbers of speciﬁc IFN-γ-secreting cells were
detected at the lowest dose analyzed only when RHDV-VLP-2 was
used. As expected, mice injected with control RHDV-VLPs did not
show any signiﬁcant response. Animals infected with VV-OVA
without any previous treatment had 1200±536 spots per 106
splenocytes of speciﬁc IFN-γ-secreting cells, six days after infection.
This value is in a similar range than the ones from mice immunized
with the chimeric RHDV-VLPs at the highest dose used. Therefore,
although both chimeric RHDV-VLPs-OVA constructs were able to
induce speciﬁc IFN-γ-secreting cells, insertion of the SIINFEKL
peptide in the amino terminal position (RHDV-VLP-2) was more
immunogenic than insertion in position 306 for induction of CTLs
and anti-viral immunity.
Additionally, another mechanism for immune protection against a
viral challenge is to induce enough speciﬁc memory CTLs. Therefore,
cytotoxic activity was measured by an in vivo CTL assay (Le Bon et al.,
2006) (Fig. 6A), where a low ﬂuorescence peak of SIINFEKL-pulsed
cells was used to calculate the percentage of speciﬁc killing compared
with unpulsed high ﬂuorescence cells injected in mice, as described in
Materials and methods.
Without any viral infection, only the animals inoculated with
RHDV-VLP-2 generated speciﬁc and functional CTL activity both at
40 μg (54.2%±15) and 8 μg (8.9%±3.2) dose of inoculation, whereas
RHDV-VLP-306 was only able to generate detectable CTL activity at the
higher dose (23.3%±10), and this was signiﬁcantly lower than that
induced by RHDV-VLP-2 (Fig. 6B). After infection with recombinant
VV-OVA, all groups of mice exhibited a high level of cytotoxic activity
(90–100%) (Fig. 6A).
Fig. 7. Viral titers per gram of ovaries in mice immunized with the different RHDV-VLPs
and subsequently challenged with VV-OVA. Mice were infected with VV-OVA 6 days
before analysis. Columns indicate viral titers after immunizationwith 2 doses of either 8
or 40 mg of RHDV-VLPs after VV-OVA challenge. White columns indicate immunization
with RHDV-VLP, grey columns for RHDV-VLP-2 and black columns for RHDV-VLP-306.
The data shown are the means of results obtained in duplicates for groups of threemice,
with the error bars representing one standard deviation above the mean. Data is
representative of two independent experiments (⁎ indicate pb0.05 and + indicate
p=0.1). Detection limit in the assay was 4 pfu/g.
Fig. 6. OVA-speciﬁc CTL cell responses in VLP immunized mice by measuring SIINFEKL-speciﬁc cytotoxic activity using in vivo CTL assay as described in Materials and methods. Groups of
three mice were twice inoculated with 8 or 40 μg of the different RHDV-VLPS: RHDV-VLP, RHDV-VLP-2 and RHDV-VLP-306. A control group for 100% of lysis, was set with a group of mice
infected i.p.withVV-OVA. (A)Cytotoxic responseswere assessed 7days latermeasuring thepercentage of speciﬁc lysis. Histograms represent target cells stainedwith high concentration of
CFSE (control cells, right) and peptide-pulsed target cells stained with low concentration of CFSE (left). The data shown is from one representative mice per group. (B) Average of speciﬁc
lysis per group ofmice. The column colours indicate the different RHDV-VLP: RHDV-VLP (white), RHDV-VLP-2 (grey) and RHDV-VLP-306 (black). The data shown are themeans of results
obtained in groups of three mice, with the error bars representing one standard deviation above the mean. Data are representative of two independent experiments.
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Finally, to determinewhether or not the immune response induced
by the chimeric RHDV-VLPs was effective against a viral challenge,
viral titers in ovaries were measured 6 days after infection with VV-
OVA, in mice untreated or mice previously inoculated twice with the
recombinant RHDV-VLPs in the absence of adjuvant. Viral titers in
mice previously inoculated with either 8 or 40 μg of control RHDV-
VLPs (Fig. 7) were in the same range to the ones induced in untreated
mice infected with VV-OVA (6±0.3×107 pfu/g). When mice were
twice inoculated with 40 μg of RHDV-VLP-306, there was a two-
logarithm reduction in virus titers, as compared with those from mice
inoculated with control RHDV-VLP, indicating that some extent of
protective immunity had been generated. Surprisingly, VV-OVA titers
decreased to undetectable levels (limit of detection in our assay was
4 pfu/g) in ovaries from mice immunized with RHDV-VLP-2 (Fig. 7).
Viral titers from mice inoculated twice with 8 μg of the chimeric VLPs
exhibited a non signiﬁcant reduction as compared with those from
mice inoculated with control RHDV-VLPs.
In conclusion, immunization of mice with the chimeric VLPs at the
highest dose tested elicited great viral titer reductions upon a VV-OVA
challenge, suggesting that the immune response induced by the
chimeric VLPs was able to copewith the viral infection. Again, the data
obtained indicated that insertion of the foreign immunogenic peptide
at the N-terminus of VP60 protein rendered better results than the
insertion at the exposed loop.
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VLPs have clearly demonstrated their potential as vectors for
vaccination (reviewed in Dyer, Renner, and Bachmann, 2006;
Jennings and Bachmann, 2008; Ludwig and Wagner, 2007) and
have proven to be a potent CTL inducer when compared with other
vectors (Allsopp et al., 1996). Recombinant VLPs derived from NV
and other human noroviruses have been used to induce systemic
and mucosal immune responses in mice (Ball et al., 1998; Guerrero
et al., 2001; Nicollier-Jamot et al., 2004; Periwal et al., 2003; Xia,
Farkas, and Jiang, 2007), and they are currently being evaluated in
human clinical trials (Ball et al., 1999; Tacket et al., 2003).
Norovirus-derived VLPs have also been used to immunize calves
and pigs (Han et al., 2006; Souza et al., 2007). In addition, VLPs
derived from other calicivirus genera like RHDV (Lagovirus) and
feline calicivirus (Vesivirus) have been shown to be highly
immunogenic (Boga et al., 1997; Di Martino, Marsilio, and Roy,
2007; Laurent et al., 1994; Nagesha, Wang, and Hyatt, 1999; Plana-
Duran et al., 1996). Taken together, these results indicate that
calicivirus VLPs could be excellent candidates to induce a potent
immune response to foreign antigens inserted in their particulate
structure and therefore to be a vaccine vector. However, chimeric
calicivirus VLPs for vaccine purpose have not been reported.
We have developed a system for the generation of chimeric VLPs
derived from RHDV that has shown a powerful capacity to elicit a
potent anti-viral response. We have also compared the immunogeni-
city induced by a foreign T cell epitope inserted at two different sites
within the capsid structure. In vitro, both chimeric RHDV-VLPs not
only activated DCs for TNF-α secretion but they also were processed
and presented to speciﬁc T cells. Additional experiments in vivo
revealed that mice immunized with chimeric RHDV-VLPs-OVA with-
out adjuvant were able to induce speciﬁc cellular responses. More
importantly, immunization with chimeric RHDV-VLPs without adju-
vant was able to resolve or to reduce an infection by a recombinant
vaccinia virus expressing OVA protein.
Nowadays, the attention is focused on the immunological pattern
of VLPs and studies have shown their immunomodulation potential
when interacting with DCs (Moron et al., 2003). DCs are essential for
activating the innate and adaptive immunity, and the particulate
nature of the RHDV-VLPs, in the size range of around 40 nm, appears
to be optimal for uptake by DCs for processing and presentation by
MHC and for promoting DC maturation and migration (Gamvrellis et
al., 2004). Several mechanisms responsible for the processing of
exogenous antigens in the MHC class I pathway have been described
(Rock, 1996), which are generally called cross-presentation. Cross-
presentation is the process whereby APCs acquire, process and
present exogenous antigen as peptides bound to MHC class I
molecules to CD8+ T cells (reviewed in Heath and Carbone, 2001).
In the present study, we demonstrated that although chimeric RHDV-
VLPs are exogenous antigens, they are presented by BM-DCs in the
context of MHC class I as evidenced by stimulation of hybridoma cells
B3Z in vitro. Cross-presentation of VLPs has been reported to occur via
a TAP-independent, endosomal pathway, or by a TAP-dependent,
endosome to cytosol pathway (Ruedl et al., 2002). To initiate cross-
presentation, APCs must both capture extracellular antigens and
receive speciﬁc activation signals, a process known as cross-priming
where type I IFN has been described to play an important role (Le Bon
et al., 2003). To gain insight into type I IFN contribution to the cross-
presentation of our chimeric RHDV-VLPs, type I receptor knock-out
BM-DCs were tested for antigen presentation in vitro. Our results
show that cross-presentation of the OVA epitope was independent of
type I IFN in the conditions tested (data not shown). Thus, cross-
presentation of chimeric RHDV-VLPs would follow a type I IFN
independent pathway that will require further investigation. Stimula-
tion of DCs by papillomavirus-like particles has been shown to involve
IFN-α secretion and it is mediated by MyD88 (Yang et al., 2004). Ourresults suggest that type I IFNs do not play a mayor role, but MyD88
implication remains to be elucidated for RHDV-VLPs.
CD8+ effector T cells are central mediators of anti-viral immunity.
These cells have been found to exert their anti-viral functions by at
least two distinct mechanisms. First, CD8+ effector T cells can
recognize and kill virus-infected cells either via perforin-dependent
lysis or through Fas–Fas ligand interaction, leading to apoptosis of the
target cell (Kagi et al., 1994; Topham, Tripp, and Doherty, 1997).
Second, virus-speciﬁc CD8+ T cells are potent producers of anti-viral
cytokines, in particular IFN-γ, which may attenuate viral replication
(Ramshaw et al., 1997). The relative importance of these two different
effector mechanisms (cell lysis versus anti-viral cytokines) in the
elimination of a viral infection is hypothesized to be heavily
inﬂuenced by the virus and its life cycle. Thus, resolution of cytopathic
viruses is thought to be mediated mainly by soluble mediators,
whereas cytotoxicity should be crucial for the clearance of a non-
cytopathic virus (Kagi and Hengartner, 1996). VLPs from porcine
parvovirus have been previously reported to be processed by MHC
class I pathway by cross-presentation (Moron et al., 2003) for
activation of CD8+ T cells which are essential for the clearance of
intracellular pathogens such a virus (Sedlik et al., 1999; Sedlik et al.,
1997). The stimulation of this effective response is based on the
induction of high frequency, efﬁciency and avidity CTLs (Sedlik et al.,
2000). In our system, the fact that both chimeric RHDV-VLPs not only
induce speciﬁc CTLs but also IFN-γ secreting cells indicated that
chimeric RHDV-VLPs might constitute excellent vaccine platforms
against both, cytopathic or non-cytopathic viruses, as they stimulate
both effector mechanisms.
Immunization of mice with chimeric VLPs induced a reduction in
viral levels upon a VV-OVA challenge (Fig. 7). Moreover, immuniza-
tion with chimeric RHDV-VLP-2 at the highest dose tested was able to
resolve VV-OVA infection. Considering that chimeric RHDV-VLP-2 was
the most efﬁcient one at inducing speciﬁc CTLs and IFN-γ producing
cells (Fig. 5 and 6), these two mechanisms might be the primary
candidates to explain viral clearance. In addition, RHDV-VLP-306 was
able to induce some detectable level of speciﬁc antibodies (data not
shown) which did not correlate with protection (Fig. 7). Further
experiments will determine the relative role of each mechanism in
viral clearance.
Native RHDV-VLPs have been used to confer complete protection
against RHD in immunized rabbits. Recently, Peacey et al. reported a
procedure to chemically conjugate whole proteins and peptides to
VLPs from RHDV (Peacey et al., 2007). They later showed that
prophylactic immunization with the chemically coupled RHDV-VLPs
administered with adjuvant has the capacity to elicit a potent cell-
mediated and anti-tumor response (Peacey et al., 2008). Our results
are in agreement and further extend those of Peacey et al. obtained
with antigen conjugated to RHDV-VLPs. Firstly, the data presented in
this work demonstrated induction of a different type of immunity,
namely anti-viral immunity by induction of speciﬁc IFN-γ secreting
cells and CTLs. Secondly, chimeric RHDV-VLPs used to immunize mice
did not require the use of adjuvants, as the chemically engineered did
(Peacey et al., 2008).
Finally, we have analyzed two potential sites to insert foreign
epitopes into RHDV-VLPs. Both constructs were shown to be
immunogenic but the one at the N-terminus, which is predicted to
be buried in the internal face of the VLPs, exhibited a higher degree of
immunogenicity for cell-mediated responses against VV-OVA infec-
tion. On the other hand, the novel insertion site located within a
predicted exposed loop at the P2 subdomain of RHDV capsid protein,
might constitute a suitable insertion site for B cell epitopes to induce
speciﬁc antibodies. The P2 subdomain, located at the surface of the
capsid, is an immunodominant region and contains the highest
variability in the genome among caliciviruses. It contains the
determinants of strain speciﬁcity, receptor binding (Chen et al.,
2004; Tan, Meller, and Jiang, 2006), and potential neutralizing
Table 1
Oligonucleotide primers used for cloning.
Primer Sequence (5′ to 3′)a
Bac1F GACTCCAAGTGTGTGGGTGAAGTC
Bac1R CACGCCCGATGTTAAATATGTCC
BacHAF CTAGAAGATCTGGTACCGTTATTAGTACATTTATTAAGCGCTAGATTCTG
T93F CGATGGCATGGACCCCGGCGTTGTG
T93R CACAACGCCGGGGTCCATGCCATCG
PolihedF TAAATAGATCTATAAATATGGAGGGCAAAGCCCGC
KpnISgRHDR TCGACGGTACCATAGCTTACTTTAAACTATAAACCCA
2GSF TAAATAGATCTATAAATATGGGATCCAAAGCCCGC
306GSF GCAAGTTACCCTGGATCCAACGCAACC
306GSR GGTTGCGTTGGATCCAGGGTAACTTGC
3OVA2F GATCTCAACTGGAGAGCATCATCAATTTCGAGAAACTTACCGAGG
3OVA2R GATCCCTCGGTAAGTTTCTCGAAATTGATGATGCTCTCCAGTTGA
a Restriction site sequences are underlined. Start and stop codons are shown in
boldface.
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characteristics in principle appropriate for an efﬁcient insertion site
intended for foreign B cell epitopes. This is the case for porcine
parvovirus derived VLPs, where T cell epitopes elicit efﬁcient immune
responses when inserted at the N-terminus of the VP2 protein, but
neither the N nor the C termini of the protein can be used to insert
foreign B cell epitopes (Sedlik et al., 1995), which must be inserted at
exposed loops, in order to render an efﬁcient speciﬁc immune
response (Rueda et al., 1999). Work is in progress to analyze the
ability of chimeric RHDV-VLPs to induce an immune response against
foreign B cell epitopes inserted at different locations within the capsid
protein.
It has been shown that pre-existing antibody responses against
VLPs exert a detrimental effect on the efﬁcacy of chimeric VLP-based
vaccines (Da Silva et al., 2001). The use of different VLP scaffolds in
prime-boost regimens to deliver the same antigen is a promising
strategy to increase the efﬁcacy and usefulness of this type of vaccines
(Da Silva, Schiller, and Kast, 2003). In the case of RHDV-VLPswhich are
derived from a rabbit virus to which no pre-existing immunity is
expected in humans or livestock species, they represent a suitable
choice of delivery system and further extend the arsenal of VLPs to use
for prime-boost regimens.
In conclusion our data demonstrated that the chimeric VLPs were
able to protect mice from a viral challenge, suggesting the potential
suitability of these constructions for new vaccine development against
animal and human viral infections.
Materials and methods
Viruses, cells and mice
Derivatives of Autographa californica nuclear polyhedrosis virus
(AcMNPV) were used to obtain the recombinant baculoviruses
expressing RHDV-VLPs. Baculoviruses were propagated in insect cell
lines grown in suspension or monolayer cultures at 28°C in TNM-FH
medium (Sigma) supplemented with 5% fetal calf serum (Gibco).
Spodoptera frugiperda cells (SF9) were used for generation of
recombinant baculoviruses, plaque assays, and the preparation of
high titer viral stocks. Trichoplusia ni cells (H5) were used for high
level expression of recombinant proteins.
Recombinant vaccinia virus (VV) expressing ovalbumin (VV-OVA)
were originally obtained from J. Yewdell (National Institute of Health,
Bethesda, Maryland, U.S.A.) (Restifo et al., 1995). Vaccinia virus was
grown and titrated in Vero cells as previously described (Earl et al.,
2001).
Mice, C57BL/6JOlaHsd (Harlan) of 7- to 8-wk-old age were used
for immunization and for DCs primary cultures. Bone marrow from
type I IFN-R KO mice in a C57BL/6 genetic background was kindly
donated by Dr. N. Sevilla and was used for DCs primary cultures.
Construction of recombinant baculovirus transfer vectors
The primers used in this study are all shown in Table 1. The
baculovirus transfer vector chosen to express the different VP60
constructs was plasmid pBacPAK8HA. This plasmid is a derivative of
pBacPAK8 (Clontech), in which several restriction sites were elimi-
nated from the multiple cloning site. To generate pBacPAK8HA, ﬁrst,
pBacPAK8 was digested with BamHI and XbaI, blunt ended, and
religated. The resulting plasmid, pBacPAK8XB, was used as template
for a PCR reaction using the primer pair BacHAF/Bac1R. After gel
puriﬁcation (FlexiPrep Kit, Amersham Pharmacia) of the PCR product,
the DNA fragment was digested with BglII and HindIII, and inserted
into the plasmid pBacPAK8XB, previously digested with the same
restriction enzymes, generating pBacPAK8HA.
A DNA fragment containing the coding sequences of proteins VP60
and VP2, and the 3′ untranslated region of RHDV (strain AST/89), wasobtained by PCR using as template plasmid pUC2.4-1, which contained
the full-length RHDV subgenomic RNA (Barcena et al., 2004), and the
primer pair PolihedF/KpnISgRHDR. The PCR product obtained was
digested with BglII and KpnI and inserted into unique restriction sites
of pBacPAK8HA, creating pHAPhSubG. This plasmid was subsequently
modiﬁed to eliminate a natural BamHI site present in the VP60 gene,
without changing the encoded amino acid sequence of the protein. For
this purpose, two separate PCR reactions were performed using the
primer pairs Bac1F/T93R and T93F/KpnISgRHDR, and plasmid
pHAPhSubG as template. The PCR products obtainedwere gel puriﬁed,
denatured and annealed together in a secondary PCR in which the
extended template was ampliﬁed using the external primers
PolihedF/KpnISgRHDR. The PCR product obtained was digested with
BglII and KpnI and inserted into unique restriction sites of pBacPA-
K8HA, generating pHAPhSubGB.
The next step was the engineering by site-directed mutagenesis of
unique BamHI sites at deﬁned locations within VP60 gene: at the
region corresponding to amino acid positions 2 and 3 (plasmid
pHAPh2GS), and at the region corresponding to amino acid positions
306 and 307 (plasmid pHAPh306GS). To generate pHAPh2GS, a PCR
was performed using the primer pair 2GSF/KpnISgRHDR, and plasmid
pHAPhSubGB as template. The PCR product obtained was digested
with BglII and BstEII and inserted into unique restriction sites of
pHAPhSubGB, creating pHAPh2GS. Plasmid pHAPh306GS was gener-
ated using two sequential PCRs. First, two separate PCR reactions were
performed using the primer pairs PolihedF/306GSF and 306GSR/
KpnISgRHDR, and plasmid pHAPhSubGB as template. The PCR
products obtainedwere gel puriﬁed, denatured and annealed together
in a secondary PCR in which the extended template was ampliﬁed
using the external primers PolihedF/KpnISgRHDR. The PCR product
obtained was digested with BglII and KpnI and inserted into unique
restriction sites of pBacPAK8HA, generating pHAPh306GS.
Finally, a DNA fragment containing the coding sequence of the
immunogenic peptide SIINFEKL derived from OVA protein, plus 3
upstream (QLE) and 2 downstream (TE) ﬂanking amino acids was
generated by annealing synthetic oligonucleotides 3OVA2F and
3OVA2R, leaving BamHI compatible ends. The annealed primers
were subsequently ligated into plasmids pHAPh2GS and pHAPh306GS,
previously linearized by BamHI digestion and dephosphorilated,
creating plasmids pHAVP60-2OVA and pHAVP60-306OVA. All the
inserted sequences in the resulting recombinant plasmids were
veriﬁed by sequence analyses.
Generation of recombinant baculoviruses
All recombinant baculoviruses were produced using the BacPAK
baculovirus expression system (Clontech) as described previously
(Barcena et al., 2004). Brieﬂy, monolayers of SF9 insect cells were co-
transfected with recombinant transfer vectors and Bsu36I triple-cut
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gen). Recombinant baculoviruses were selected on the basis of their
LacZ-negative phenotypes, plaque puriﬁed, and propagated as
described elsewhere (King and Possee, 1992).
Expression and puriﬁcation of the recombinant RHDV-VLPs
The recombinant VP60 and the chimeric VP60 constructs were
expressed and the self-assembled VLPs were puriﬁed by previously
described methods (Almanza et al., 2008). Brieﬂy, H5 insect cell
monolayers were infected with recombinant baculoviruses at a
multiplicity of infection of 10. After incubation (6–7 days, 28 °C)
infected cells were scraped into the medium. The culture medium
was then clariﬁed by centrifugation (at 10,000 rpm for 10 min with
a GSA rotor), and the supernatant was centrifuged at 26,000 rpm for
2 h with a Beckman SW28 rotor. The pelleted material was
resuspended in 0.2 M phosphate-buffered saline for VLPs (PBS-V;
0.2 M sodium phosphate, 0.1 M NaCl, pH 6.0), extracted twice with
Vertrel® XF, and subjected to centrifugation (at 35,000 rpm for 2 h
with a Beckman SW55 rotor) through a 20% sucrose cushion of
1.5 ml made with PBS-V. Subsequently, the pellet was suspended in
a solution of CsCl (0.42 g/ml) and subjected to isopycnic gradient
centrifugation at 35,000 rpm for 18 h in a Beckman SW55 rotor. The
visible opalescent band in the CsCl gradient was collected by
micropipetting, diluted in PBS-V, and pelleted by centrifugation at
26,000 rpm for 2 h in a Sorvall TH-641 rotor to remove CsCl. The
pellet was ﬁnally resuspended in PBS-V containing protease
inhibitors (Complete, Roche) and stored at 4°C. The protein
concentrations of the VLP preparations were determined with a
bicinchoninic acid protein assay kit (BCA protein assay kit, Pierce).
Electron microscopy
Samples (approximately 5 μl) were applied to glowdischarged
carbon-coated grids for 2 min. and negatively stained with 2% (wt/
vol) aqueous uranyl acetate. Micrographs were recorded with a Jeol
1200 EXII electron microscope operating at 100 kV at a nominal
magniﬁcation of ×40,000.
Mouse bone marrow derived dendritic cells (BM-DCs) generation
BM-DCs were generated from cultures of bone marrow cells of
C57Bl/6 and type I IFN-R KO mice. They were prepared as described
previously (Montoya et al., 2002). Brieﬂy, bone marrow was extracted
from the tibia and femur, and cell suspensions were cultured in RPMI
1640 complete medium (Gibco) containing 10% heat-inactivated fetal
calf serum (FCS), 50 μM 2-ME, 100 U/mL penicillin, 100 μg/mL
streptomycin, 100 U/mL polymyxin B (Sigma), and 20 ng/mL
recombinant murine granulocyte-macrophage colony-stimulating
factor (rmGM-CSF) (R and D Systems, Abingdon, Oxon, United
Kingdom). Fresh medium was given every other day. CD11c+ ranged
between 95% and 98% without any further sorting or treatment. The
BM progenitors were incubated at 37°C in 5% CO2 in Petri dishes for
8 days as previously described (Lutz et al., 1999) and then immature
BM-DCs were used for the antigen presentation assay.
DC activation and antigen presentation assay
Different concentrations of our different RHDV-VLPs (RHDV-VLP-
2, RHDV-VLP-306 and negative control RHDV-VLP) were plated in
triplicates with murine immature BM-DCs (105 cells/well) and they
were incubated for 6–7 h in 96-well culture microplates in a ﬁnal
volume of 100 μl of RPMI 1640 complete medium. Activation of DCs
was analyzed by TNF-α release in the supernatant using a speciﬁc
ELISA (R&D Systems, Abingdon, Oxon, United Kingdom). Detection
limit in ELISA was 9 pg/ml. Then, BM-DCs were thoroughly washedand 105 cell/well of speciﬁc CD8+ hybridoma (B3Z) recognizing
SIINFEKL peptide (Karttunen, Sanderson, and Shastri, 1992) were
added and incubated overnight at 37°C in 5% CO2. Antigen
presentation to B3Z presented in combination with H2-Kb MHC-I
was analyzed by IL-2 release in the supernatant using an speciﬁc
ELISA (R&D Systems, Abingdon, Oxon, United Kingdom). Detection
limit in ELISA was 6 pg/ml. BM-DCs cells stimulated only with
SIINFEKL peptide (ProImmune, Abingdon, UK) were used as control
of presentation efﬁciency range in our in vitro experiment (Moron et
al., 2003).
Immunization protocol
The following immunization schemewas used in two independent
experiments: female C57BL/6JOlaHsd (Harlan) of 7- to 8-wk-old age,
kept under speciﬁc-pathogen-free-conditions, were randomly divided
in groups of 6 animals and intraperitoneally inoculated twice in
2 week intervals with 40 μg or 8 μg of VLPs resuspended in 200 μl of
sterile PBS (a control group was inoculated with PBS alone). No
adjuvant was used in the immunisations. Two weeks after the second
VLP inoculation, three animals in each group were challenged
intraperitoneally with 106 pfu/mice of VV-OVA.
Evaluation of cellular responses and CTL activity
Two weeks after the second immunization, spleen cells were
collected and analyzed for speciﬁc IFN-γ production by ELISPOT Set
following manufactures instructions (Becton Dickinson UK). Spleen
cellswere added to triplicatewells at concentrations of 104,105 and 106
cells/well with SIINFEKL peptide (ProImmune, Abingdon, UK) at a con-
centration of 10−6 M per well. Triplicate wells with 106 cells without
peptide were used to estimate the non-speciﬁc activation. As positive
control, triplicate wells with 106 cells were stimulated with phytohe-
magglutinin (PHA) (Sigma) at a concentration of 10 μg/ml per well.
For in vivo CTL assays, naïve spleen cells were pulsed ex-vivo for 1 h
with 1 nM of SIINFEKL peptide. After extensive washing, cells were
labelled with 0.1 μM CFSE (CFSElo) (Molecular Probes, The Nether-
lands). A control population, splenocytes unpulsed with peptide, was
labelled with 1 μM CFSE (CFSEhi). CFSElo and CFSEhi cells were mixed
in a 1:1 ratio and injected intravenously into naïve or immunized
animals. After 18 h, spleens were removed and single-cell suspensions
analyzed by ﬂow cytometry to determine the ratio of CFSElo to CFSEhi
cells. The percentage of speciﬁc lysis was calculated as follows: % of
speciﬁc lysis=100− {100×(% CFSElo immunised/% CFSEhi immu-
nised)−(% CFSElo control/% CFSEhi control).
Evaluation of viral levels
Viral titers in ovaries of individual mice were determined at day 6
after infection by a plaque assay using Vero cells {Restifo, 1995 #100}.
Detection limit was 4 pfu/g.
Statistical analysis
Experimental groups were compared through ANOVA followed by
Tukey–Kramer post hoc test for multiple comparisons of unpaired
observations. The signiﬁcance level was established at pb0.05 and all
the analyses were carried out with the NCSS 2004 and PASS 2005
software (Kavysville, Utah, USA).
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